- Trials with a EudraCT protocol (79)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
79 result(s) found for: Feeding disorder.
Displaying page 1 of 4.
EudraCT Number: 2014-002624-28 | Sponsor Protocol Number: FIT-EU-04 | Start Date*: 2015-09-24 |
Sponsor Name:Nutrinia Ltd. | ||
Full Title: A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. | ||
Medical condition: Gastrointestinal Maturation in Preterm Infants. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005348-92 | Sponsor Protocol Number: PROGASS | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO | |||||||||||||
Full Title: PROGASS PRucalopride On the GAstreonteric transit in Systemic Sclerosis | |||||||||||||
Medical condition: Sysemic sclerosis with gastroenteric involvement (constipation) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004937-15 | Sponsor Protocol Number: BNC210.006 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:BIONOMICS LIMITED | |||||||||||||
Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001879-33 | Sponsor Protocol Number: ESR-18-13811 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) | |||||||||||||
Medical condition: Patients with EGFR mutant NSCLC according to TP53 mutational status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001490-40 | Sponsor Protocol Number: 3005019 | Start Date*: 2012-04-03 | ||||||||||||||||
Sponsor Name:ORION CORPORATION ORION PHARMA | ||||||||||||||||||
Full Title: Comparative evaluation of the effects of dexmedetomidine and propofol on patient/ventilator interaction in difficult-to-wean mechanically ventilated patients; a prospective, open, randomised, mul... | ||||||||||||||||||
Medical condition: Patients requiring mechanical ventilation and sedation in the ICU | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001237-42 | Sponsor Protocol Number: F1J-XM-HMED(a) | Start Date*: 2005-01-27 |
Sponsor Name:Lilly S.A. | ||
Full Title: Open-Label Duloxetine Extension phase in Patients Who Have Completed the F1J-MC-HMDG Clinical Trial Fase de extensión abierta con duloxetina en aquellos pacientes que hayan finalizado el ensayo cl... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001635-21 | Sponsor Protocol Number: VIA-2291-02 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:VIA PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients wi... | |||||||||||||
Medical condition: Carotid Stenosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002905-89 | Sponsor Protocol Number: 20186 | Start Date*: 2022-10-19 |
Sponsor Name:BAYER AG | ||
Full Title: An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults f... | ||
Medical condition: Treatment of children with chronic kidney disease and proteinuria | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002626-22 | Sponsor Protocol Number: F1J-MC-HMDV(a) | Start Date*: 2005-01-24 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder | ||
Medical condition: Generalized Anxiety Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004890-29 | Sponsor Protocol Number: FIT-PIV | Start Date*: 2023-03-09 | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004460-63 | Sponsor Protocol Number: EXPO | Start Date*: 2019-07-01 | ||||||||||||||||
Sponsor Name:South London and Maudsley NHS Foundation Trust [...] | ||||||||||||||||||
Full Title: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opi... | ||||||||||||||||||
Medical condition: Opiod addiction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002638-54 | Sponsor Protocol Number: ALN-AS1-002 | Start Date*: 2017-12-20 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Comple... | |||||||||||||
Medical condition: Acute Intermittent Porphyria (AIP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022706-41 | Sponsor Protocol Number: NIC - 05 (NOCRY-a) | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:MENARINI RICERCHE S.P.A. | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, parallel group pilot study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic babies not responder to conventiona... | |||||||||||||
Medical condition: Infant colic | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003197-57 | Sponsor Protocol Number: A0081181 | Start Date*: 2012-11-09 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Pfizer Worldwide Research and Development | ||||||||||||||||||||||||||||||||||||||
Full Title: A MULTIPLE DOSE PHARMACOKINETIC OPEN-LABEL STUDY OF PREGABALIN (LYRICA) IN HEALTHY LACTATING WOMEN | ||||||||||||||||||||||||||||||||||||||
Medical condition: neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia neuropathic pain related to spinal cord injury (US), fibromyalgia (US, JP) treatment of central and periphe... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000032-27 | Sponsor Protocol Number: GUP05007 | Start Date*: 2005-10-19 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||
Full Title: MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term | |||||||||||||
Medical condition: Charcot-Marie-Tooth disease type 1A CMT1A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000043-74 | Sponsor Protocol Number: PNAS0122 | Start Date*: 2023-07-27 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications | ||
Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001513-13 | Sponsor Protocol Number: LAL-CL04 | Start Date*: 2011-10-24 | |||||||||||||||||||||
Sponsor Name:Synageva Biopharma Corp. | |||||||||||||||||||||||
Full Title: AN OPEN LABEL MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SBC-102 IN ADULT SUBJECTS WITH LIVER DYSFUNCTION DUE TO LYSOSOMAL ACID LIPASE DEFICIENCY WH... | |||||||||||||||||||||||
Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-003927-11 | Sponsor Protocol Number: A7501008 | Start Date*: 2005-08-04 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000117-39 | Sponsor Protocol Number: A2301 | Start Date*: 2011-06-14 | |||||||||||
Sponsor Name:Ixodes AG. | |||||||||||||
Full Title: A Phase 3 randomized, double-blind, placebo-controlled study of SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosis in su... | |||||||||||||
Medical condition: Lyme borreliosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004565-14 | Sponsor Protocol Number: ECP-002e | Start Date*: 2014-02-13 | |||||||||||
Sponsor Name:Edimer Pharmaceuticals, Inc. | |||||||||||||
Full Title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002 | |||||||||||||
Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1.... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
